3 results
Approved WMOCompleted
The purpose of this studie is to evaluate the bioequivalence of canagliflozin.
Approved WMOWill not start
The purpose of this study is to evaluate the possible risks and efficacy (improvement of disease) with an experimental oral study drug named eliglustat in pediatric patients from 2 to 18 years with Gaucher disease.
Approved WMORecruiting
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 as a single agent (Phase Ia) or in combination with a checkpoint inhibitor targeting the PD-L1/PD-1 axis (Phase Ib) in patients with locally advanced or…